Deutsche Bank AG Makes New $4.28 Million Investment in Bicara Therapeutics Inc. $BCAX

Deutsche Bank AG bought a new stake in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) during the 2nd quarter, Holdings Channel reports. The fund bought 144,010 shares of the company’s stock, valued at approximately $4,276,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in BCAX. Legal & General Group Plc lifted its stake in Bicara Therapeutics by 64.1% in the second quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after acquiring an additional 1,233 shares during the period. Tower Research Capital LLC TRC increased its position in Bicara Therapeutics by 419.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock valued at $44,000 after purchasing an additional 3,866 shares during the period. Mirae Asset Global Investments Co. Ltd. purchased a new position in Bicara Therapeutics during the 4th quarter valued at $45,000. Larson Financial Group LLC raised its holdings in Bicara Therapeutics by 1,015.5% in the 3rd quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock worth $62,000 after purchasing an additional 3,595 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd raised its holdings in Bicara Therapeutics by 385.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,775 shares of the company’s stock worth $97,000 after purchasing an additional 4,585 shares in the last quarter.

Bicara Therapeutics Price Performance

Shares of NASDAQ BCAX opened at $24.58 on Wednesday. Bicara Therapeutics Inc. has a 1 year low of $10.30 and a 1 year high of $30.99. The firm has a 50-day moving average of $26.64 and a 200 day moving average of $22.23. The stock has a market cap of $1.63 billion, a P/E ratio of -7.93 and a beta of -0.75.

Bicara Therapeutics (NASDAQ:BCAX) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.82) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.82). Research analysts expect that Bicara Therapeutics Inc. will post -3.45 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Claire Mazumdar sold 10,000 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $27.98, for a total value of $279,800.00. Following the sale, the chief executive officer directly owned 362,152 shares of the company’s stock, valued at approximately $10,133,012.96. This represents a 2.69% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Ivan Hyep sold 12,500 shares of the firm’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $27.97, for a total transaction of $349,625.00. Following the sale, the chief financial officer owned 129,855 shares of the company’s stock, valued at approximately $3,632,044.35. This represents a 8.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 108,000 shares of company stock valued at $3,079,236. 13.80% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of brokerages have recently weighed in on BCAX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Bicara Therapeutics in a research note on Monday, July 6th. BMO Capital Markets started coverage on shares of Bicara Therapeutics in a research note on Tuesday, August 18th. They issued an “outperform” rating and a $35.00 price target for the company. The Goldman Sachs Group raised their price objective on shares of Bicara Therapeutics from $18.00 to $20.00 and gave the stock a “neutral” rating in a report on Wednesday, August 12th. Wedbush raised their price objective on shares of Bicara Therapeutics from $30.00 to $33.00 and gave the stock an “outperform” rating in a report on Wednesday, August 12th. Finally, Wall Street Zen raised Bicara Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Sunday, May 24th. Two analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $32.64.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.